市場調查報告書

慢性發炎性脫髓鞘性多發性神經病(CIDP) - 市場洞察,流行病學,市場預測 2028年

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Market Insight, Epidemiology and Market Forecast - 2030

出版商 DelveInsight Business Research LLP 商品編碼 524395
出版日期 內容資訊 英文 150 Pages
商品交期: 最快1-2個工作天內
價格
慢性發炎性脫髓鞘性多發性神經病(CIDP) - 市場洞察,流行病學,市場預測 2028年 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Market Insight, Epidemiology and Market Forecast - 2030
出版日期: 2020年01月01日內容資訊: 英文 150 Pages
簡介

主要7個國家(美國,英國,德國,法國,義大利,西班牙,日本)的慢性發炎性脫髓鞘性多發性神經病(CIDP)的2018年的患病數推算為4萬5127人,市場規模4億7,350萬美元。美國擁有最大罹患數,歐盟5國法國的患病數最高。

本報告提供主要7個國家(美國,英國,德國,法國,義大利,西班牙,日本)的慢性發炎性脫髓鞘性多發性神經病(CIDP)市場調查,總括性彙整市場概要,疾病概要和現行的治療方法,新藥的簡介,整體及各國的市場趨勢,流行病學的預測,市場規模,患病數的變化與預測,未滿足需求,市場成長要素及障礙等資訊。

目錄

第1章 主要洞察

第2章 慢性發炎性脫髓鞘性多發性神經病(CIDP)市場概要

  • 慢性發炎性脫髓鞘性多發性神經病(CIDP)的市場佔有率(實際成果值)
  • 慢性發炎性脫髓鞘性多發性神經病(CIDP)的市場佔有率(預測值)

第3章 慢性發炎性脫髓鞘性多發性神經病(CIDP):疾病的背景和概要

  • 簡介
  • 分類
  • 臨床表現
  • 慢性發炎性脫髓鞘性多發性神經病(CIDP)與格林-巴利症候群比較
  • 與慢性發炎性脫髓鞘性多發性神經病(CIDP)關聯的疾病
  • 醫院
  • 診斷
    • 診斷標準
    • 鑑別診斷
    • 美國神經學會(AAN)的電器診斷標準
    • Koski以及其他的標準
    • 歐洲神經學會(EFNS)及末梢神經學會(PNS)

第4章 流行病學和患者人口

  • 主要調查結果

第5章 主要7個國家慢性發炎性脫髓鞘性多發性神經病(CIDP)的整體患病數

第6章 美國的流行病學

  • 假設和理論的根據
  • 慢性發炎性脫髓鞘性多發性神經病(CIDP)的整體患病數
  • 慢性發炎性脫髓鞘性多發性神經病(CIDP)的患病數:性別
  • 慢性發炎性脫髓鞘性多發性神經病(CIDP)的患病數:疾病類型
  • 慢性發炎性脫髓鞘性多發性神經病(CIDP)的患病數:各年齡

第7章 歐洲5個國家的流行病學

  • 德國
    • 假設和理論的根據
    • 慢性發炎性脫髓鞘性多發性神經病(CIDP)的整體患病數
    • 慢性發炎性脫髓鞘性多發性神經病(CIDP)的患病數:性別
    • 慢性發炎性脫髓鞘性多發性神經病(CIDP)的患病數:疾病類型
    • 慢性發炎性脫髓鞘性多發性神經病(CIDP)的患病數:各年齡
  • 法國
    • 假設和理論的根據
    • 慢性發炎性脫髓鞘性多發性神經病(CIDP)的整體患病數
    • 慢性發炎性脫髓鞘性多發性神經病(CIDP)的患病數:性別
    • 慢性發炎性脫髓鞘性多發性神經病(CIDP)的患病數:疾病類型
    • 慢性發炎性脫髓鞘性多發性神經病(CIDP)的患病數:各年齡
  • 義大利
    • 假設和理論的根據
    • 慢性發炎性脫髓鞘性多發性神經病(CIDP)的整體患病數
    • 慢性發炎性脫髓鞘性多發性神經病(CIDP)的患病數:性別
    • 慢性發炎性脫髓鞘性多發性神經病(CIDP)的患病數:疾病類型
    • 慢性發炎性脫髓鞘性多發性神經病(CIDP)的患病數:各年齡
  • 西班牙
    • 假設和理論的根據
    • 慢性發炎性脫髓鞘性多發性神經病(CIDP)的整體患病數
    • 慢性發炎性脫髓鞘性多發性神經病(CIDP)的患病數:性別
    • 慢性發炎性脫髓鞘性多發性神經病(CIDP)的患病數:疾病類型
    • 慢性發炎性脫髓鞘性多發性神經病(CIDP)的患病數:各年齡
  • 英國
    • 假設和理論的根據
    • 慢性發炎性脫髓鞘性多發性神經病(CIDP)的整體患病數
    • 慢性發炎性脫髓鞘性多發性神經病(CIDP)的患病數:性別
    • 慢性發炎性脫髓鞘性多發性神經病(CIDP)的患病數:疾病類型
    • 慢性發炎性脫髓鞘性多發性神經病(CIDP)的患病數:各年齡
  • 日本
    • 假設和理論的根據
    • 慢性發炎性脫髓鞘性多發性神經病(CIDP)的整體患病數
    • 慢性發炎性脫髓鞘性多發性神經病(CIDP)的患病數:性別
    • 慢性發炎性脫髓鞘性多發性神經病(CIDP)的患病數:疾病類型
    • 慢性發炎性脫髓鞘性多發性神經病(CIDP)的患病數:各年齡

第8章 慢性發炎性脫髓鞘性多發性神經病(CIDP)的治療方法

  • 可用治療的生物活性
  • 歐洲神經學會(EFNS)及末梢神經學會(PNS)的治療指南
  • 美國神經病學學會(AAN) - CIDP循證指南
  • CIDP的治療 - Cochrane系統評價

第9章 治療流程

第10章 未滿足需求

第11章 已上市治療藥

  • puribijen:CSL Behring
    • 醫藥品概要
    • 法規的里程碑
    • 其他開發活動
    • 安全性和有效性
    • 產品簡介
  • Privigen:CSL Behring
    • 醫藥品概要
    • 其他開發活動
  • Gamunex-C:Grifols / Kiderion Biopharma
  • Kenketsu Glovenin-I:Nihon Pharmaceutical
  • Tegeline:LFB

第12章 新藥

  • 關鍵交叉競爭
  • GGS-CIDP:Teijin製藥
    • 醫藥品概要
    • 其他開發活動
    • 臨床開發
    • 安全性和有效性
    • 產品簡介
  • Newgam:OctaPharma
    • 醫藥品概要
  • HyQvia:Shire/武田藥品工業
  • I10E:LFB
  • MD-1003:MedDay Pharmaceuticals
  • GNbAC1:GeNeuro Pharmaceuticals

第13章 市場分析慢性發炎性脫髓鞘性多發性神經病(CIDP):主要7個國家

  • 主要調查結果
  • 主要7個國家的市場規模

第14章 美國:市場預測

  • 美國的市場規模
    • 市場規模
    • 市場規模:新藥

第15章 歐洲5個國家:市場預測

  • 德國的市場規模
    • 市場規模
    • 市場規模:新藥
  • 法國的市場規模
    • 市場規模
    • 市場規模:新藥
  • 義大利的市場規模
    • 市場規模
    • 市場規模:新藥
  • 西班牙的市場規模
    • 市場規模
    • 市場規模:新藥
  • 英國的市場規模
    • 市場規模
    • 市場規模:新藥

第16章 日本:市場預測

  • 日本的市場規模
    • 市場規模
    • 市場規模:新藥模

第17章 市場成長要素

第18章 市場障礙

第19章 附錄

  • 調查手法

第20章 DelveInsight的服務內容

第21章 免責聲明

第22章 關於DelveInsight

目錄
Product Code: DIMI0056

DelveInsight's "Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), historical and forecasted epidemiology as well as the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) market report provides current treatment practices, emerging drugs, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) market share of the individual therapies, current and forecasted Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) market Size from 2017 to 2030 segmented by seven major markets. The Report also covers current Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2017-2030

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Disease Understanding and Treatment Algorithm

The DelveInsight Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) market report gives a thorough understanding of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis and treatment.

Diagnosis

This segment of the report covers the detailed diagnostic methods or tests for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP).

Treatment

It covers the details of conventional and current medical therapies available in the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) market for the treatment of the condition. It also provides Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) treatment algorithms and guidelines in the United States, Europe, and Japan.

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Epidemiology

The Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) epidemiology division provide insights about historical and current Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings

The disease epidemiology covered in the report provides historical as well as forecasted Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2017 to 2030.

Country Wise- Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Epidemiology

The epidemiology segment also provides the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Drug Chapters

Drug chapter segment of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) report encloses the detailed analysis of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Marketed Drugs

The report provides the details of the marketed product available for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) treatment.

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Emerging Drugs

The report provides the details of the emerging therapies under the late and mid-stage of development for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) treatment.

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Outlook

The Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) market outlook of the report helps to build the detailed comprehension of the historic, current, and forecasted Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a thorough detail of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) market in 7MM is expected to change in the study period 2017-2030.

Key Findings

This section includes a glimpse of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) market in 7MM.

The United States Market Outlook

This section provides the total Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) market size and market size by therapies in the United States.

EU-5 Countries: Market Outlook

The total Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom is provided in this section.

Japan Market Outlook

The total Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) market size and market size by therapies in Japan is also mentioned.

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) market or expected to get launched in the market during the study period 2017-2030. The analysis covers Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) market uptake by drugs; patient uptake by therapies; and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase II, and Phase III stage. It also analyses Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) key players involved in developing targeted therapeutics.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing, patent details and other information for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) emerging therapies.

Reimbursement Scenario in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we take reimbursement into consideration to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

KOL- Views

To keep up with current market trends, we take KOLs and SME's opinion working in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) market trend. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

We perform Competitive and Market Intelligence analysis of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market by using various Competitive Intelligence tools that include - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report

  • The report covers the descriptive overview of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
  • Comprehensive insight has been provided into the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) epidemiology and treatment in the 7MM
  • Additionally, an all-inclusive account of both the current and emerging therapies for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
  • A detailed review of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) market; historical and forecasted is included in the report, covering drug outreach in the 7MM
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) market

Report Highlights

  • In the coming years, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
  • The companies and academics are working to assess challenges and seek opportunities that could influence Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
  • Major players are involved in developing therapies for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). Launch of emerging therapies will significantly impact the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) market
  • A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
  • Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Pipeline Analysis
  • Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Report Key Strengths

  • 11 Years Forecast
  • 7MM Coverage

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Epidemiology Segmentation

  • Key Cross Competition
  • Highly Analyzed Market
  • Drugs Uptake

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers

Key Questions

Market Insights:

  • What was the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) market share (%) distribution in 2017 and how it would look like in 2030?
  • What would be the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) total market size as well as market size by therapies across the 7MM during the forecast period (2017-2030)?
  • What are the key findings pertaining to the market across 7MM and which country will have the largest Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) market size during the forecast period (2017-2030)?
  • At what CAGR, the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) market is expected to grow in 7MM during the forecast period (2017-2030)?
  • What would be the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) market outlook across the 7MM during the forecast period (2017-2030)?
  • What would be the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) market growth till 2030, and what will be the resultant market Size in the year 2030?
  • How would the market drivers, barriers and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:

  • What is the disease risk, burden and unmet needs of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)?
  • What is the historical Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What would be the forecasted patient pool of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)?
  • Out of all 7MM countries, which country would have the highest prevalent population of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) during the forecast period (2017-2030)?
  • At what CAGR the population is expected to grow in 7MM during the forecast period (2017-2030)?
  • Current Treatment Scenario, Marketed Drugs and Emerging Therapies:
  • What are the current options for the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) treatment, along with the approved therapy?
  • What are the current treatment guidelines for the treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in the USA, Europe, and Japan?
  • What are the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy, etc.?
  • How many companies are developing therapies for the treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)?
  • How many therapies are developed by each company for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) treatment?
  • How many are emerging therapies in mid-stage, and late stage of development for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) treatment?
  • What are the key collaborations (Industry - Industry, Industry - Academia), Mergers and acquisitions, licensing activities related to the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) therapies?
  • What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and their status?
  • What are the key designations that have been granted for the emerging therapies for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)?
  • What are the global historical and forecasted market of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)?

Reasons to buy

  • The report will help in developing business strategies by understanding trends shaping and driving the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) market
  • To understand the future market competition in the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) market and Insightful review of the key market drivers and barriers
  • Organize sales and marketing efforts by identifying the best opportunities for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
  • Organize sales and marketing efforts by identifying the best opportunities for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) market
  • To understand the future market competition in the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) market

Table of Contents

1. Key Insights

2. Executive Summary of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

3. Competitive Intelligence Analysis for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

4. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP): Market Overview at a Glance

  • 4.1. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Total Market Share (%) Distribution in 2017
  • 4.2. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Total Market Share (%) Distribution in 2030

5. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP): Disease Background and Overview

  • 5.1. Introduction
  • 5.2. Sign and Symptoms
  • 5.3. Pathophysiology
  • 5.4. Risk Factors
  • 5.5. Diagnosis

6. Patient Journey

7. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Epidemiology and Patient Population

  • 7.1. Epidemiology Key Findings
  • 7.2. Assumptions and Rationale: 7MM
  • 7.3. Epidemiology Scenario: 7MM
    • 7.3.1. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Epidemiology Scenario in the 7MM (2017-2030)
  • 7.4. United States Epidemiology
    • 7.4.1. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Epidemiology Scenario in the United States (2017-2030)
  • 7.5. EU-5 Country-wise Epidemiology
    • 7.5.1. Germany Epidemiology
      • 7.5.1.1. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Epidemiology Scenario in Germany (2017-2030)
    • 7.5.2. France Epidemiology
      • 7.5.2.1. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Epidemiology Scenario in France (2017-2030)
    • 7.5.3. Italy Epidemiology
      • 7.5.3.1. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Epidemiology Scenario in Italy (2017-2030)
    • 7.5.4. Spain Epidemiology
      • 7.5.4.1. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Epidemiology Scenario in Spain (2017-2030)
    • 7.5.5. United Kingdom Epidemiology
      • 7.5.5.1. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Epidemiology Scenario in the United Kingdom (2017-2030)
    • 7.5.6. Japan Epidemiology
      • 7.5.6.1. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Epidemiology Scenario in Japan (2017-2030)

8. Treatment Algorithm, Current Treatment, and Medical Practices

  • 8.1. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Treatment and Management
  • 8.2. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Treatment Algorithm

9. Unmet Needs

10. Key Endpoints of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Treatment

11. Marketed Products

  • 11.1. List of Marketed Products in the 7MM
  • 11.2. Drug Name: Company Name
    • 11.2.1. Product Description
    • 11.2.2. Regulatory Milestones
    • 11.2.3. Other Developmental Activities
    • 11.2.4. Pivotal Clinical Trials
    • 11.2.5. Summary of Pivotal Clinical Trial

List to be continued in report

12. Emerging Therapies

  • 12.1. Key Cross
  • 12.2. Drug Name: Company Name
    • 12.2.1. Product Description
    • 12.2.2. Other Developmental Activities
    • 12.2.3. Clinical Development
    • 12.2.4. Safety and Efficacy
    • 12.2.5. Product Profile

List to be continued in report

13. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP): Seven Major Market Analysis

  • 13.1. Key Findings
  • 13.2. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size in 7MM
  • 13.3. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Therapies in the 7MM

14. Attribute analysis

15. 7MM: Market Outlook

  • 15.1. United States: Market Size
    • 15.1.1. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Total Market Size in the United States
    • 15.1.2. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Therapies in the United States
  • 15.2. EU-5 countries: Market Size and Outlook
  • 15.3. Germany Market Size
    • 15.3.1. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Total Market Size in Germany
    • 15.3.2. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Therapies in Germany
  • 15.4. France Market Size
    • 15.4.1. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Total Market Size in France
    • 15.4.2. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Therapies in France
  • 15.5. Italy Market Size
    • 15.5.1. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Total Market Size in Italy
    • 15.5.2. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Therapies in Italy
  • 15.6. Spain Market Size
    • 15.6.1. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Total Market Size in Spain
    • 15.6.2. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Therapies in Spain
  • 15.7. United Kingdom Market Size
    • 15.7.1. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Total Market Size in the United Kingdom
    • 15.7.2. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Therapies in the United Kingdom
  • 15.8. Japan Market Outlook
    • 15.8.1. Japan Market Size
    • 15.8.2. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Total Market Size in Japan
    • 15.8.3. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size by Therapies in Japan

16. Access and Reimbursement Overview of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

  • 20.1. Bibliography
  • 20.2. Report Methodology

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

List of Tables

  • Table 1 : 7MM Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Epidemiology (2017-2030)
  • Table 2 : 7MM Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Diagnosed and Treatable Cases (2017-2030)
  • Table 3 : Disease% Epidemiology in the United States (2017-2030)
  • Table 4 : Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Diagnosed and Treatable Cases in the United States (2017-2030)
  • Table 5 : Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Epidemiology in Germany (2017-2030)
  • Table 6 : Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Diagnosed and Treatable Cases in Germany (2017-2030)
  • Table 7 : Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Epidemiology in France (2017-2030)
  • Table 8 : Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Diagnosed and Treatable Cases in France (2017-2030)
  • Table 9 : Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Epidemiology in Italy (2017-2030)
  • Table 10 : Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Diagnosed and Treatable Cases in Italy (2017-2030)
  • Table 11 : Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Epidemiology in Spain (2017-2030)
  • Table 12 : Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Diagnosed and Treatable Cases in Spain (2017-2030)
  • Table 13 : Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Epidemiology in the UK (2017-2030)
  • Table 14 : Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Diagnosed and Treatable Cases in the UK (2017-2030)
  • Table 15 : Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Epidemiology in Japan (2017-2030)
  • Table 16 : Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Diagnosed and Treatable Cases in Japan (2017-2030)
  • Table 17 : Drug Name, Clinical Trials by Recruitment status
  • Table 18 : Drug Name, Clinical Trials by Zone
  • Table 19 : Total Seven Major Market Size in USD, Million (2017-2030)
  • Table 20 : Region-wise Market Size in USD, Million (2017-2030)
  • Table 21 : 7MM-Market Size by Therapy in USD, Million (2017-2030)
  • Table 22 : United States Market Size in USD, Million (2017-2030)
  • Table 23 : United States Market Size by Therapy in USD, Million (2017-2030)
  • Table 24 : Germany Market Size in USD, Million (2017-2030)
  • Table 25 : Germany Market Size by Therapy in USD, Million (2017-2030)
  • Table 26 : France Market Size in USD, Million (2017-2030)
  • Table 27 : France Market Size by Therapy in USD, Million (2017-2030)
  • Table 28 : Italy Market Size in USD, Million (2017-2030)
  • Table 29 : Italy Market Size by Therapy in USD, Million (2017-2030)
  • Table 30 : Spain Market Size in USD, Million (2017-2030)
  • Table 31 : Spain Market Size by Therapy in USD, Million (2017-2030)
  • Table 32 : United Kingdom Market Size in USD, Million (2017-2030)
  • Table 33 : United Kingdom Market Size by Therapy in USD, Million (2017-2030)
  • Table 34 : Japan Market Size in USD, Million (2017-2030)
  • Table 35 : Japan Market Size by Therapy in USD, Million (2017-2030)

List of Figures

  • Figure 1 : 7MM Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Epidemiology (2017-2030)
  • Figure 2 : 7MM Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Diagnosed and Treatable Cases (2017-2030)
  • Figure 3 : Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Epidemiology in the United States (2017-2030)
  • Figure 4 : Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Diagnosed and Treatable Cases in the United States (2017-2030)
  • Figure 5 : Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Epidemiology in Germany (2017-2030)
  • Figure 6 : Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Diagnosed and Treatable Cases in Germany (2017-2030)
  • Figure 7 : Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Epidemiology in France (2017-2030)
  • Figure 8 : Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Diagnosed and Treatable Cases in France (2017-2030)
  • Figure 9 : Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Epidemiology in Italy (2017-2030)
  • Figure 10 : Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Diagnosed and Treatable Cases in Italy (2017-2030)
  • Figure 11 : Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Epidemiology in Spain (2017-2030)
  • Figure 12 : Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Diagnosed and Treatable Cases in Spain (2017-2030)
  • Figure 13 : Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Epidemiology in the UK (2017-2030)
  • Figure 14 : Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Diagnosed and Treatable Cases in the UK (2017-2030)
  • Figure 15 : Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Epidemiology in Japan (2017-2030)
  • Figure 16 : Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Diagnosed and Treatable Cases in Japan (2017-2030)
  • Figure 17 : Drug Name, Clinical Trials by Recruitment status
  • Figure 18 : Drug Name, Clinical Trials by Zone
  • Figure 19 : Total Seven Major Market Size in USD, Million (2017-2030)
  • Figure 20 : Region-wise Market Size in USD, Million (2017-2030)
  • Figure 21 : 7MM-Market Size by Therapy in USD, Million (2017-2030)
  • Figure 22 : United States Market Size in USD, Million (2017-2030)
  • Figure 23 : United States Market Size by Therapy in USD, Million (2017-2030)
  • Figure 24 : Germany Market Size in USD, Million (2017-2030)
  • Figure 25 : Germany Market Size by Therapy in USD, Million (2017-2030)
  • Figure 26 : France Market Size in USD, Million (2017-2030)
  • Figure 27 : France Market Size by Therapy in USD, Million (2017-2030)
  • Figure 28 : Italy Market Size in USD, Million (2017-2030)
  • Figure 29 : Italy Market Size by Therapy in USD, Million (2017-2030)
  • Figure 30 : Spain Market Size in USD, Million (2017-2030)
  • Figure 31 : Spain Market Size by Therapy in USD, Million (2017-2030)
  • Figure 32 : United Kingdom Market Size in USD, Million (2017-2030)
  • Figure 33 : United Kingdom Market Size by Therapy in USD, Million (2017-2030)
  • Figure 34 : Japan Market Size in USD, Million (2017-2030)
  • Figure 35 : Japan Market Size by Therapy in USD, Million (2017-2030)